Protecting eyesight with a small molecule in a broad band of mutations


Key patent granted.

Press release


Mireca’s key patent application receives “Notice of Allowance” from USPTO.

Tübingen, Germany, February 20th, 2019 – Mireca Medicines GmbH, an ophthalmology start-up company developing treatments for inherited retinal degeneration, receives the validating “Notice of Allowance” from the USPTO for its proprietary formulation and medical use patent application “Targeted liposomal delivery of cGMP analogues” (PCT/EP2016/055659).

German ophthalmology start-up Mireca Medicines GmbH receives “Notice of Allowance” for its patent application “Targeted liposomal delivery of cGMP analogues” (PCT/EP2016/055659) from the United States Patent and Trademark Office (USPTO), declaring that the application has been examined and is allowed for issuance as a patent. The invention relates to means and methods for targeted drug delivery of cGMP analogues for retinal and other diseases. All inventors are related to the group of founders and shareholders of Mireca, which wholly owns this patent.

Mireca’s lead program of developing LP-DF003, a liposomal cGMP analogue formulation, in Retinitis Pigmentosa (RP), Leber’s congenital amaurosis (LCA) and Stargardt’s disease (STGD) is a first application of this patent. Further benefits and protection for this development program comes from our orphan drug designation (ODD) in the lead indication (EU/3/15/1462). Also wholly owned patent applications “PKG antagonists” (PCT/EP2017/066113) and “PKG agonists” (PCT/EP2017/071859), both protecting the routes of manufacturing +250 further cGMP analogues as composition of matter, provide for an extension of the cGMP approach into other, more common neurodegenerative retinal diseases like age-related macular degeneration and diabetic retinopathy, as well as other disease indications.

“Being rewarded with an issued US patent for the core of our invention is very rewarding and a validation of Mireca’s set of intellectual property, manufacturing and (pre)-clinical assets”, comments Prof. Dr. François Paquet-Durand, CSO of Mireca. “Allowance of Mireca’s first patent application crucially supports our current fundraising, aimed at driving forward clinical development of LP-DF003 in the near future”, adds Barbara Brunnhuber, CEO of Mireca Medicines GmbH.

 About Retinal Degeneration

Hereditary retinal degeneration is a neurodegenerative condition that leads to loss of photoreceptors and ultimately blindness; the conditions still lack effective treatments. The diseases are caused by gene mutations, whereas the genes in question code for a variety of proteins with different functions, although often related to photoreceptor specific activities. Based on Retinal Information Network data[1], the number of disease genes amounts to over 250, with an even higher number of individual mutations in each of these genes. Amongst the diseases are Retinitis Pigmentosa (RP), Leber’s congenital amaurosis (LCA), and Stargardt’s disease (STGD), which, depending on the actual variant, affect between 1:3.000 – 1:30.000 individuals. Mireca believes that around 450,000 persons are affected by these conditions in the EU, US and Japan alone. Inherited retinal degenerations are today untreatable, and while individually they are rare, together they constitute a major cause of severe visual loss and blindness in the working age population.

About Mireca Medicines GmbH

Mireca is a pre-clinical stage ophthalmology start-up company seated in Tübingen (Germany) aiming to bring its targeted, small molecule drug candidate to patients suffering from inherited retinal degeneration like Retinitis Pigmentosa (RP), Leber’s congenital amaurosis (LCA), and Stargardt’s disease (STGD) covering a broad range of mutations.

The company creates value through leveraging the combination of orphan size drug development, orphan market protection and a large combined market size protected by its proprietary intellectual property.


For further information, please contact
Mireca Medicines GmbH
Barbara Brunnhuber, CEO
Phone: +31 6 23 93 69 66
E-mail: bb@mireca.eu

[1] http://sph.uth.edu/Retnet/

ARVO 2019: Emerging Drug for RP Evaluated in Safety & Tolerability Study

01.05.2019, FFB Eye on the Cure Research News, Francois Paquet-Durand, PhD, chief scientific officer at the company Mireca, discusses an emerging drug for retinitis pigmentosa, and other inherited retinal diseases. The compound is active across many mutations and reaches the retina in a liposomal delivery system (like a "nano capsule").  The positive safety & tolerability study was presented in a poster at the 2019 meeting of the Association for Research in Vision and Ophthalmology (ARVO), April 28-May 2, 2019, in Vancouver, Canada.

Erbliche Netzhautdegeneration: Neuer RP-Wirkstoff vom Start-up

01.04.2018, transkript, Erbliche Netzhauterkrankungen, wie Retinitis pigmentosa (RP) betreffen mindestens zwei Millionen Menschen weltweit. Noch gibt es kaum Wege, die Degeneration der Stäbchenzellen in der Netzhaut und damit den fortschreitenden Sehverlust aufzuhalten. Ein Strukturanalogon des Signalmoleküls cGMP bremst den Verlust der Photorezeptoren bei ganz unterschiedlichen Krankheitsformen, berichteten Mitte Marz Forscher der Mireca Medicines GmbH, einer Ausgründung der Universitätsklinik Tübingen (PNAS, doi: 10.1073/pnas.1718792115).

Mireca announces publication detailing its cGMP approach in science journal PNAS

14.03.2018, Mireca Medicines GmbH, an ophthalmology start-up company developing treatments for inherited retinal degeneration, announces the publication of an article by Eleonora Vighi et al. “Combination of cGMP analogue and drug delivery system provides functional protection in hereditary retinal degeneration”, in Proceedings of the National Academy of Sciences of the United States of America (PNAS).

Weiterer Schritt in der Entwicklung eines neuen Medikaments für erbliche Netzhautdegeneration. Aktuell im Wissenschaftsjournal PNAS veröffentlicht

14.03.2018, Universitätsklinikum Tübingen, Bei bestimmten seltenen Netzhauterkrankungen kommt es im Auge zum Absterben von Photorezeptoren, deren Ursache unterschiedliche krankheitsauslösende Mutationen sein können. Für die Entwicklung von Therapien besteht zudem die Herausforderung, dass die Netzhaut durch die sogenannte „Blut-Hirn-Schranke“ gegen die meisten Medikamente abgeschirmt ist. Jetzt ist es Wissenschaftlern des Forschungsinstituts für Augenheilkunde Tübingen, aus Lund (Schweden), Modena und Reggio Emilia (Italien) gelungen, einen Signalweg zu finden, über den eine neuartige Medikamentensubstanz diese Schranke passieren kann.

Mireca: a new drug for stopping the progression of eye diseases

04.09.2017, Healthcare Industry BW, A team of researchers from several EU countries has developed a new drug that stops the progression of hereditary retinal diseases. The project partners founded a company called Mireca Medicines GmbH in the city of Tübingen to bring the drug to market.

Start-up in the garage – a location with prospects

06.04.2017, BioRegio STERN, Newly established start-up wins award – Mireca Medicines GmbH develops treatment for hereditary eye disease and receives Innovation Award of the biotechnology regions in Germany.